


# Unitaid's Vector Control Portfolio

RBM Vector Control Working Group Meeting

Matthew Black & Kelsey Barrett  
February 2023



# Unitaid: A global development agency



Number of Unitaid projects in countries, 2020

## VISION

Equitable access to health innovations to ensure healthy lives and promote well-being for all

## MISSION

We expand the reach of the best health products for those who need them most

# Unitaid Brings Lifesaving Tools to People in LMICs

Without Unitaid  
vital health tools  
would not exist  
today



All HIV medicines in low- and middle-income countries (LMICs)



All tests to detect TB bacterial load and all medicines to treat drug-resistant TB



All tools to prevent malaria



All paediatric formulations for HIV, TB, malaria  
Groundwork for national cervical cancer elimination

ACT-A  
Therapeutics  
partnership



# Unitaid accelerates equitable access to innovative health products

Access areas	Innovation & Availability	Quality	Affordability	Supply & Delivery	Demand & Adoption	
Examples of Unitaid interventions	Late stage product development/reformulations	Prequalification	Price negotiations	Distribution optimization	Global Policy & Guidelines	
	Post registration clinical trials	In-country registration	Pooled procurement	Technical Assistance/Incentives to manufacturers	Country Policy and Guidelines	
		Local manufacturing	Volume guarantee	Capacity building	Large-scale pilots	
			Co-pay	Forecasting	Evidence generation: feasibility, cost-effectiveness	
			Intellectual Property		Behavior change	

# 2023-2027 Strategic Objectives and Programmatic Priorities

## STRATEGIC OBJECTIVES

# 1

### Accelerate the introduction and adoption of key health products

- Boost the **development** of fit-for-purpose health products
- Use **market shaping approaches** to enable suitable, affordable, quality supply
- Support **product adoption and scale up** in countries as part of simple, effective and evidence-based models of care

# 2

### Create systemic conditions for sustainable, equitable access

- Establish an **enabling environment** for access, including IP and regulation
- Support innovative **supply models & approaches**, including local manufacturing and technology transfer
- Disseminate **knowledge and evidence** on access

# 3

### Foster inclusive and demand-driven partnerships for innovation

- Maximise the engagement of **affected communities** and responsiveness to their needs
- Maximise alignment and synergies with **governments, in-country stakeholders, affected communities and civil society organizations**
- Further develop **global alliances** for product scaleup

## PROGRAMMATIC PRIORITIES



HIV &  
co-infections



TB



Malaria



Women &  
children's health



Respond to  
global health  
emergencies




Cross-cutting  
technologies  
& topics

- **Reinforces** our traditional core area of work: e.g., grant making, especially for HIV, TB, malaria; scale-up
- **Formalizes** work in areas we introduced and demonstrated, e.g., local manufacturing; engagement with affected communities
- **Expands** our mandate to new areas, e.g., making healthcare greener; responding to global health emergencies; disseminating knowledge and evidence on access



# Programmatic priorities


 Cross-linkages with improving health outcomes for women and children

 HIV & co-infections

 TB

 Malaria

 Women & children's health

 Respond to global health emergencies

Sustain effectiveness of prevention & treatment

Enable TB prevention tools for high-risk groups

Introduce and optimize prevention tools

Improve access to better tools for safe pregnancy and birth for women and newborns

Optimize and enable scale of AHD packages of care

Accelerate access to new detection tools

Improve access to quality case management

Improve quality of clinical care packages for COVID-19

Drive HCV elimination through testing and prevention

Accelerate adoption of new drugs and regimens

Increase access to screen & treat for cervical cancer and STIs

Improve child survival with triage and treatment tools

Accelerate access to self-testing & integrated diagnostics

Decentralize testing and treatment for COVID-19

Long acting & new technologies

Intellectual Property, regulatory and innovative supply models


## Malaria priority 1: Introduce and optimize prevention tools (vector control, chemoprevention, vaccines)

*Adoption of new tools and approaches, in the most impactful combinations*

### Illustrative portfolio of topics & interventions

- **Short-term (current):** optimize delivery of malaria chemoprevention (IPTi) and ensure access to quality-assured drugs; evaluate new vector control tools (spatial repellents and ivermectin)
- **Mid-term (2-3 years):** optimize deployment of prevention tools e.g. through at-scale pilots, innovative delivery approaches, and generating evidence to guide policy and prioritization.
- **Long-term (4-5 years):** lay the groundwork for transformational new prevention tools (e.g. genetically modified mosquitos, long-acting technologies and vaccines)

# Unitaid's current malaria portfolio (US\$ 327 million)








\*Recently closed



# New Nets Project








 <b>Lead Grantee</b>	Innovative Vector Control Consortium (IVCC)
 <b>Grant Period</b>	2018-2022
 <b>Grant Value</b>	US\$66M
 <b>Project countries</b>	Benin, Burkina Faso, Rwanda, Mali, Mozambique, Nigeria, Cote d'Ivoire, Liberia, Ghana, DRC, Malawi, Niger, Cameroon, and Burundi




 <b>Grant Impact</b>	<i>Introduce new long-lasting insecticide-treated nets (LLINs) in areas of insecticide resistance</i>
---	---

# Advancing Spatial Repellents for Vector-borne Disease Control



	<b>Lead Grantee</b>	University of Notre Dame
	<b>Grant Period</b>	2019 - 2024
	<b>Grant Value</b>	US\$ 33.7M
	<b>Project countries</b>	Kenya, Mali, Sri Lanka, Uganda








 **Grant Impact**

*Evaluate slow-release repellents that drive mosquitoes from inhabited areas*

# Broad One Health Endectocide-based Malaria Intervention in Africa (BOHEMIA)



 <b>Lead Grantee</b>	ISGlobal
 <b>Grant Period</b>	2019 - 2024
 <b>Grant Value</b>	US\$ 25M
 <b>Project countries</b>	Mozambique, Kenya



**Grant Impact**

*Develop a new complementary new-class vector control tool, ivermectin (endectocides)*





# IMPACT: Long-acting injectable formulation of ivermectin as a new vector control tool to reduce malaria transmission

Technology
<p><b>BEPO<sup>®</sup> advanced injectable in-situ forming depot</b></p> <ul style="list-style-type: none"> <li>uses a combo 2 bioresorbable copolymers + solvent as excipients.               <ul style="list-style-type: none"> <li>Drug release from days to months.</li> <li>Simple manufacturing process</li> </ul> </li> <li>Contraception + HIV PreP funded by BMGF</li> </ul>

Target Indications	
<i>Malaria vector control</i>	<p><i>BEPO<sup>®</sup>- IVM:</i> Injectable subcutaneous 3-month long-acting formulation of ivermectin</p>

Timeline*		
Preclinical Development	Clinical Development	Regulatory & Commercialization
2020 – 2023	2023 – 2025	2026

\*Unitaid funded IMPACT project – 2020 – 2023 up to initiation of clinical development.



# A Roadmap for Innovation- 30 key products by 2030

## Key malaria prevention tools:

- Next-generation LLINs
- Malaria vaccines
- Chemoprevention tools and approaches
- Spatial repellents
- Ivermectin MDA

